Wolfe Research initiated coverage of Ascendis Pharma (ASND) with an Outperform rating and $255 price target Yorvipath is off to a “strong” launch and “the party is only beginning,” according to the analyst, who sees $4B-pluse peak sales “looking increasingly achievable.” The stock looks priced as if Yorvipath is the whole story, leaving the derisked pipeline looking “underappreciated,” the analyst added.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Ascendis Pharma publishes results from ApproaCH Trial in JAMA Pediatrics
- Ascendis Pharma A/S: Strong Growth and Strategic Challenges
- Ascendis Pharma: Promising Growth and Strong Market Penetration Justify Buy Rating
- Strong Demand and Strategic Developments Drive Buy Rating for Ascendis Pharma
- Ascendis Pharma Reports Strong Q3 2025 Performance